NEW YORK (GenomeWeb News) – Atossa Genetics today announced it has acquired intellectual property from the Dr. Susan Love Research Foundation covering a biomarker test for breast cancer.
Atossa has acquired all ownership rights to US Patent No. 7,879,614 and pending US application 11/958,597. Both patents cover the manufacture, use, and sale of a biomarker test for the analysis of carbohydrates contained in nipple aspirate fluid using a sensitive detection reagent such as a Schiff's reagent.
Atossa is paying an upfront fee as well as patent-based royalties on aggregate net sales in the countries with issued patents, it said. No further financial details about the transaction were disclosed.
In a clinical trial of nipple aspirate fluid from 28 women 30 to 52 years old at the Breast Care Clinic at the University of California, San Francisco, the test was positive for all 12 women with known cancer and negative with 12 of 16 women without cancer.
"We intend to continue the clinical research needed to determine if these early results are valid and whether the biomarker can form the basis of a useful clinical screening test," Steven Quay, chairman and CEO, of Atossa said.
Based in Seattle, Atossa develops molecular diagnostics for breast cancer. Last month the firm announced it raised $6.6 million in a private placement with accredited investors. Proceeds will be used to create a commercial manufacturing process for its Mammary Aspirate Specimen Cytology Test System, or MASCT.